Benefits of cladribine tablets on the proportion of patients with multiple sclerosis free from clinical and radiological indicators of disease activity in the CLARITY EXTENSION study

被引：0
|
作者：
Giovannoni, G. [1 ]
Comi, G. [2 ,3 ]
Cook, S. [4 ]
Rieckmann, P. [5 ]
Rammohan, K. [6 ]
Soelberg-Sorensen, P. [7 ]
Vermersch, P. [8 ]
Adeniji, A. [9 ]
Dangond, F. [9 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[2] Univ Vita Salute San Raffaele, Osped San Raffaele, Dept Neurol, Milan, Italy
[3] Univ Vita Salute San Raffaele, Osped San Raffaele, Inst Expt Neurol, Milan, Italy
[4] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA
[5] Akad Krankenhaus Sozialstiftung, Neurol Klin, Bamberg, Germany
[6] Ohio State Univ Hosp, Columbus, OH 43210 USA
[7] Copenhagen Univ Hosp, Dept Neurol, Danish MS Ctr, Copenhagen, Denmark
[8] Univ Lille, CHU Lille, LIRIC, INSERM,U 995, Lille, France
[9] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
基金：
英国医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P636
引用
收藏
页码：300 / 301
页数：2
相关论文
共 50 条
  • [1] Cladribine tablets in high disease activity (HDA) subgroups from the CLARITY study of patients with relapsing multiple sclerosis (RMS)
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Hicking, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 203 - 204
  • [2] Effects of cladribine tablets on radiological outcomes in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Hicking, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 613 - 614
  • [3] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Hamlett, A.
    Miret, M.
    Weiner, J.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
  • [4] Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies
    Soelberg-Sorensen, Per
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Vermersch, Patrick
    Hicking, Christine
    Adeniji, Abidemi
    Dangond, Fernando
    NEUROLOGY, 2017, 88
  • [5] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Comi, Giancarlo
    Cook, Stuart D.
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony C.
    Viglietta, Vissia
    Greenberg, Steven J.
    JOURNAL OF NEUROLOGY, 2013, 260 (04) : 1136 - 1146
  • [6] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Giancarlo Comi
    Stuart D. Cook
    Gavin Giovannoni
    Kottil Rammohan
    Peter Rieckmann
    Per Soelberg Sørensen
    Patrick Vermersch
    Anthony C. Hamlett
    Vissia Viglietta
    Steven J. Greenberg
    Journal of Neurology, 2013, 260 : 1136 - 1146
  • [7] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S21 - S21
  • [8] CLARITY extension: sustained efficacy in relapsing remitting multiple sclerosis following switch from cladribine tablets to placebo in patients with high disease activity at baseline
    Vermersch, P.
    Giovannoni, G.
    Soelberg-Sorensen, P.
    Keller, B.
    Jack, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 867 - 867
  • [9] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 215 - 215
  • [10] Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies.
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Hicking, C.
    Adeniji, A.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 48 - 49
12345